Phaseline

Companies › Abdera Therapeutics

Abdera Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
225Ac-ABD147
DLL3-targeting antibody fragment conjugated with actinium-225
DLL3Phase 1Small-Cell Lung Cancer (SCLC)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06736418225Ac-ABD147Phase 1Small-Cell Lung Cancer (SCLC)OncologyJan 2027

Targets

DLL3 (1)

Companies with the same targets

Novartis Boehringer Ingelheim Daiichi Sankyo Amgen Molecular Partners AbbVie IDEAYA Biosciences Beijing Biotech Phanes Therapeutics Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.